Plexxikon Inc.

Neurocrine Biosciences, Inc.

Other

Todd Ewing

Prabha N Ibrahim

Wayne Spevak

Ying Zhang

Guoxian Wu

Martin W Rowbottom

Warren Stanfield Wade

Jack Lin

Mi Chen

Timothy Richard Coon

Neil Ashweek

Yun-Fei Zhu

Graham Beaton

Wanlong Jiang

Willy Moree

Liren Zhao

Jiazhong Zhang

Chao Zhang

Marika Nespi

Richard B Lowe

Nicole Smith

Songyuan Shi

Hanna Cho

Katrina Chan

Phuongly Pham

John Buell

Nicole Harriott

Jinghua Yu

Jianming Tsai

Jeffrey Yung Wu

Gideon Bollag

James Tsai

Ken Dong

Richard Lowe

Warren Wade

Martin Rowbottom

Compounds active on protein kinases are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases.

Compounds and methods for kinase modulation, and indications therefor

A liquid filtering bag comprises a liquid-permeable fabric and zipper. When the zipper is fully engaged, the fabric folds to form a liquid filtering bag suitable for filtering liquids. When the zipper is fully disengaged, the fabric unfolds to form a flat sheet suitable for thorough washing.

Liquid filtering bag

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R, R, R, R, R, R, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

A liquid filtering press comprises two rigid baskets that stack together in a nested fashion to squeeze a filtration bag containing an unfiltered liquid. The liquid permeable baskets permit liquid to flow out freely through the entire surface of the filtration bag while preventing direct hand-to-liquid contact during pressing. A linkage between the baskets facilitates opening, closing, and pressing operations.

Liquid filtering press

Cold-brewed compositions and methods for preparing them are disclosed that comprise the general steps of: (a) adding together ingredients comprising unheated aqueous liquid, a variety of brewing ingredients, and emulsion stabilizers comprising polysaccharides to obtain various aqueous mixtures; (b) grinding brewing ingredients amidst the obtained aqueous mixtures for a period of 30 seconds to three minutes to obtain various dispersions of finely ground brewing particles; and (c) removing brewing particles large enough to be detected by the tongue or mouth to obtain a variety of novel cold-brewed compositions that possess stabilized emulsions.

Cold brew compositions and methods

Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and/or mutant c-kit protein kinases.

Compounds active on c-kit protein kinases or mutant c-kit protein kinases having any mutations are described, as well as methods of making and using such compounds to treat diseases and conditions associated with aberrant activity of the c-kit protein kinases and mutant c-kit protein kinases.

Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein Z, Z, and Zare as described herein, compositions thereof, and uses thereof.

The present disclosure provides methods of treating a subject suffering from or at risk of a BRAF V600 mutation or BRAF fusion mutation related disease or condition, without activating the MAPK pathway or inducing expression of MAPK pathway genes in cells harboring wild-type BRAF.

Kinase modulation, and indications therefor

Compounds and salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof and uses thereof are described, wherein the compounds have formula Ia:  In certain aspects and embodiments, the described compounds or salts thereof, formulations thereof, conjugates thereof, derivatives thereof, forms thereof are active on one or more of Fms, Kit, Flt3, TrkA, TrkB and TrkC kinase protein. Also described are methods of use thereof to treat diseases and conditions, including diseases and conditions associated with activity of one or more of Fms, Kit, Flt3, TrkA, TrkB and TrkC, including rheumatoid arthritis, osteoarthritis, osteoporosis, peri-prosthetic osteolysis, systemic sclerosis, demyelinating disorders, multiple sclerosis, Charcot Marie Tooth syndrome, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, global ischemia, ulcerative colitis, Crohn's disease, immune thrombocytopenic purpura, atherosclerosis, systemic lupus erythematosis, myelopreparation for autologous transplantation, transplant rejection, glomerulonephritis, interstitial nephritis, Lupus nephritis, tubular necrosis, diabetic nephropathy, renal hypertrophy, type I diabetes, acute pain, inflammatory pain, neuropathic pain, acute myeloid leukemia, melanoma, multiple myeloma, breast cancer, prostate cancer, pancreatic cancer, lung cancer, ovarian cancer, gliomas, glioblastoma, neurofibromatosis, osteolytic bone metastases, brain metasteses, gastrointestinal stromal tumors, and giant cell tumors.

Growing community of inventors

Walnut Creek, CA, United States of America

Todd Ewing